Eileen 60 mikrogrami/13 mikrogrami/24 stundās transdermāls plāksteris Lettonie - letton - Zāļu valsts aģentūra

eileen 60 mikrogrami/13 mikrogrami/24 stundās transdermāls plāksteris

gedeon richter plc., hungary - gestodenum, ethinylestradiolum - transdermāls plāksteris - 60 µg/13 µg/24 stundās

Albumin Baxalta 200 g/l šķīdums infūzijām Lettonie - letton - Zāļu valsts aģentūra

albumin baxalta 200 g/l šķīdums infūzijām

baxalta innovations gmbh, austria - albumīns, cilvēka - Šķīdums infūzijām - 200 g/l

Diener 0,03 mg/2 mg apvalkotās tabletes Lettonie - letton - Zāļu valsts aģentūra

diener 0,03 mg/2 mg apvalkotās tabletes

laboratorios leon farma s.a., spain - ethinylestradiolum, dienogestum - apvalkotā tablete - 0,03 mg/2 mg

Vonille 60 mikrogrami/15 mikrogrami apvalkotās tabletes Lettonie - letton - Zāļu valsts aģentūra

vonille 60 mikrogrami/15 mikrogrami apvalkotās tabletes

exeltis baltics uab, lithuania - gestodenum, ethinylestradiolum - apvalkotā tablete - 60 mikrogrami/15 mikrogrami

Wilate 1000 SV/1000 SV pulveris un šķīdinātājs injekciju šķīduma pagatavošanai Lettonie - letton - Zāļu valsts aģentūra

wilate 1000 sv/1000 sv pulveris un šķīdinātājs injekciju šķīduma pagatavošanai

octapharma (ip) sprl, belgium - faktors cilvēka von willebrandi, faktoru viii koagulācijas cilvēku - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 1000 sv/1000 sv

Wilate 500 SV/500 SV pulveris un šķīdinātājs injekciju šķīduma pagatavošanai Lettonie - letton - Zāļu valsts aģentūra

wilate 500 sv/500 sv pulveris un šķīdinātājs injekciju šķīduma pagatavošanai

octapharma (ip) sprl, belgium - faktors cilvēka von willebrandi, faktoru viii koagulācijas cilvēku - pulveris un šķīdinātājs injekciju šķīduma pagatavošanai - 500 sv/500 sv

Gefitinib Mylan Union européenne - letton - EMA (European Medicines Agency)

gefitinib mylan

mylan pharmaceuticals limited - gefitinib - karcinoma, nesīkšūnu plaušas - antineoplastic agents, protein kinase inhibitors - gefitinib mylan ir norādīts kā monotherapy ārstēšanai pieaugušiem pacientiem ar lokāli papildu vai metastātiska nav maza šūnu plaušu vēzis (nsclc) ar aktivizējot egfr mutācijas‑tk.

Cegfila (previously Pegfilgrastim Mundipharma) Union européenne - letton - EMA (European Medicines Agency)

cegfila (previously pegfilgrastim mundipharma)

mundipharma corporation (ireland) limited - pegfilgrastim - neitropēnija - imunitātes stimulatori, - ilguma samazināšanās neutropenia un saslimstība ar pieaugušiem pacientiem drudža neutropenia ārstēti ar citotoksiskas ķīmijterapijas ļaundabīgo audzēju (izņemot myeloid hroniskas leikēmijas un myelodysplastic sindromi).

Comirnaty Union européenne - letton - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcīnas - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. izmantojot šo vakcīnu, kas būtu saskaņā ar oficiālās rekomendācijas.

Vaxzevria (previously COVID-19 Vaccine AstraZeneca) Union européenne - letton - EMA (European Medicines Agency)

vaxzevria (previously covid-19 vaccine astrazeneca)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vakcīnas - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. izmantojot šo vakcīnu, kas būtu saskaņā ar oficiālās rekomendācijas.